Hikal Limited (NSE:HIKAL)
India · Delayed Price · Currency is INR | Market Cap | 27.83B -3.0% |
| Revenue (ttm) | 18.51B +8.9% |
| Net Income | -50.00M |
| EPS | -0.40 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 37.36 |
| Dividend | 0.60 (0.27%) |
| Ex-Dividend Date | Sep 4, 2026 |
| Volume | 124,140 |
| Open | 225.00 |
| Previous Close | 225.40 |
| Day's Range | 225.00 - 228.68 |
| 52-Week Range | 146.25 - 261.00 |
| Beta | 0.53 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 3, 2026 |
About Hikal
Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, biotechnology, life sciences, animal health, crop protection, and specialty chemicals industries. The company operates in two segments, Pharmaceuticals and Crop Protection. It provides anti-convulsant, anti-inflammatory, analgesic, anti-parasitic, anti-lipemic, anti-histaminic, anti-depressant, anti-psychotic, anti-emetic, anti-diabetic, anti-thrombotic, anti-viral, and haemo... [Read more]
Financial Performance
Financial StatementsNews
Hikal shares fall over 7% as Q4 net profit drops 71% YoY to Rs 14.4 crore, EBITDA down 14.6%
Hikal shares declined more than 7% in early trade on May 29 after the company reported a weak set of consolidated fourth-quarter results for FY26. The stock came under selling…
Hikal reports Q4 FY26 revenue of Rs 519 crore with 20.3% EBITDA margin
Hikal Ltd., a long-term partner for global life sciences companies, has announced its audited financial results for the quarter and year ending 31st March 2026. The company's revenue for Q4…
Hikal Q4 Results: Net profit falls 71% YoY to Rs 14.4 crore, revenue down 6%
Hikal Limited reported its Q4 FY26 results with weak year-on-year performance across revenue and profitability, although the company showed improvement sequentially compared to the December quarter. F...
Pharma sector stocks surge sharply today, April 8: Sudeep Pharma rally 9.41%, KIMS up 5.52%, HIKAL jumps 5.30%
Pharmaceutical stocks showed mixed movements in early trading on April 8, 2026, with several gaining while others remained flat or declined slightly. The data reflects prices around 9:45 AM for…
Pharma sector stocsk today, Feb 12: Hikal jumps 13.46%, Zydus up 2.44%, Biocon rises 2.31%
The Indian pharma sector showed mixed performance on February 12, 2026, as of around 10:10 AM IST. The data reflects...
Hikal shares rally sharply over 10% on solid Q3 results
Hikal Ltd shares surged sharply in early trade on February 12, 2026, rallying over 10% after the company announced its...
Hikal shares rally over 12% today; Details here
Hikal’s shares saw a sharp surge of over 12% in today’s session, drawing strong market attention as trading activity intensified...
Hikal shares fall over 5% as company reports Q2 net loss and nearly 30% drop in sales
Shares of Hikal Ltd declined 5.15% to Rs 228 on Friday, November 14, after the company reported weak September quarter...
Stocks under radar today: Titagarh Rail, Polyplex, Hikal, Maithan Alloys, NIACL and more
On Friday, November 14, 2025, several stocks are under focus after reporting weak quarterly numbers or facing company-specific negative developments....
Baba Kalyani's son retains Hikal board seat amid feud
India Business News: MUMBAI: Hikal shareholders have approved the reappointment of Bharat Forge vice-chairman and joint MD Amit Kalyani to the board of the chemicals compa.
Hikal shares fall over 2% after US FDA issues warning letter for Jigani facility
Hikal Limited shares fell more than 2% in morning trade on Friday after the company disclosed that it has received a warning letter from the United States Food and Drug Administration (US FDA) regardi...
Hikal receives warning letter from US FDA for Jigani facility
Hikal Ltd., a leading pharmaceutical and chemical manufacturing company, has received a warning letter from the United States Food and Drug Administration (US FDA) concerning its manufacturing facilit...
Hikal shares fall nearly 7% after Q1 loss of Rs 22.4 crore
Shares of Hikal Ltd plunged 6.97% to ₹286.20 on the NSE during Monday’s session after the company reported a consolidated net loss of ₹22.4 crore for the quarter ended June 30, 2025 (Q1 FY26). The sto...
Hikal reports Q1 net loss of Rs 22.4 crore; revenue declines 6.5% YoY
Hikal Limited reported a net loss of ₹22.4 crore for the quarter ended June 30, 2025 (Q1 FY26), compared to a net profit of ₹5.1 crore in the same quarter last year. The decline was driven by lower re...
Hikal successfully clears ANVISA GMP audit for Bengaluru API manufacturing facility
Hikal Ltd. has announced the successful completion of the Good Manufacturing Practices (GMP) audit conducted by the Brazilian Health Regulatory Agency (ANVISA) at its manufacturing facility located in...
Hikal receives OAI classification from US FDA for Jigani facility
Hikal Limited has announced that the United States Food and Drug Administration (US FDA) has classified its recent inspection of the company’s manufacturing facility in Jigani, Bengaluru as “Official ...
Hikal share price jumps 4% as Q4 revenue rises 7.4% YoY to Rs 552 crore, net profit up 48% YoY
Hikal Limited shares jumped 4% after the company reported a strong set of numbers for Q4 FY25. As of 3:17 PM, the shares were trading 3.51% higher at Rs 421.90. Net profit surged 48% year-on-year to ₹...
Hikal Q4 Results: Revenue up 7.4% YoY to Rs 552 crore, Net Profit up 48% YoY
Hikal Limited reported a robust performance for the fourth quarter ended March 31, 2025, with net profit rising 48% year-on-year to ₹50.2 crore, compared to ₹33.9 crore in Q4 FY24. The company’s stron...
Hikal shares drop over 6% after US FDA issues six observations for Jigani facility
Hikal Ltd’s stock tumbled over 6% in early trade after the company announced it received six observations from the US Food and Drug Administration (US FDA) for its Jigani facility in Bengaluru, Karnat...
Hikal receives 6 observations for Jigani facility from US FDA
Hikal Ltd has successfully completed a US Food and Drug Administration (US FDA) inspection at its Jigani facility in Bengaluru, Karnataka. The inspection, conducted from February 3 to February 7, 2025...